丹诺医药

July 2, 2024 – TenNor will present a series of posters on its investigational new drug rifaquizinone (TNP-2092) for the treatment of medical device infections at IDWeek 2024 to be held in Los Angeles, USA from October 16 to 20, 2024.

TenNor and its collaborators from the Rothman Orthopedic Institute, Huashan Hospital of Fudan University, Velocity Clinical Research, Allucent, Pharmaron, WuXi AppTec, University of North Texas Health Science Center and Zhongnan Hospital of Wuhan University submitted eight poster presentations on rifaquizinone to IDWeek 2024. All abstracts have been accepted.

1. Efficacy of Rifaquizinone in a Murine Model of Prosthetic Joint Infection (PJI) with Fluoroquinolone-Sensitive and -Resistant Staphylococcus aureus （ID: 1829145）

2. Efficacy of Intra-Articular Administration of Rifaquizinone in Rodent Models of Implant Infection Associated with Staphylococcus aureus （ID: 1829135）

3. Safety Study of Rifaquizinone in Dogs Following Intra-Articular Administration （ID: 1829121）

4. Pharmacokinetics of Rifaquizinone in Rats and Dogs Following Intra-Articular Administration （ID: 1829129）

5. Safety, Tolerability, and Pharmacokinetics of Rifaquizinone for Injection in Healthy Participants in China: A Single-center, Double-blind, Randomized, Placebo-controlled, Phase 1 Bridge Study （ID: 1829061）

6. An Open-label Phase 1 Study in Healthy Adult Male Participants to Investigate the Absorption, Metabolism, and Excretion of [14C]-Rifaquizinone Following a Single Intravenous Administration （ID: 1829100）

7. Distribution of Rifaquizinone in Bone, Synovial Fluid and Plasma: A Phase 1 Trial in Patients Undergoing Total Hip or Knee Arthroplasty （ID: 1829093）

8. Rifaquizinone for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Multicenter, Double-Blind, Randomized, Active-Controlled, Phase 2 Trial （ID: 1820809）

IDWeek is an important conference jointly organized by the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Disease Pharmacists (SIDP).

Rifaquizinone is a multi-targeting drug conjugate specifically designed and developed for the treatment of medical device infections. It exerts its antibacterial activity by inhibiting bacterial RNA polymerase, DNA gyrase and topoisomerase IV. It shows potent activity against bacteria commonly resistant to current antibiotics, such as methicillin-resistant and quinolone-resistant Staphylococcus aureus (MRSA and QRSA), and bacterial biofilm infections associated with implanted medical devices. Rifaquizinone exhibits lower frequencies for the development of resistance than the most of traditional antibiotics.

TenNor has completed six phase 1 and phase 2 clinical trials for rifaquizinone for injection in China and the United States and is planning to conduct multiregional phase 3 clinical trials for the treatment of prosthetic joint infections (PJI) and acute bacterial skin and skin structure infections (ABSSSI). Rifaquizinone for injection has received Qualified Infectious Disease Product (QIDP), Fast Track and Orphan Drug designations form the FDA.

Annex:

TNP-2092 IDWeek 2024 Poster Presentations

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late-stage of clinical development targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com